HLB Panagen Delivers Opening Keynote on PNA at U.S. Conference

On the 3rd (local time), HLB Panagen delivered the opening keynote speech on peptide nucleic acid (PNA) at the "Oligonucleotide and Peptide Exchange 2026" held in San Francisco, USA.

On the 3rd (local time), Minchae Kim, Senior at HLB Panagen, gave the opening keynote speech on PNA at the "Oligonucleotide & Peptide Exchange 2026" held in San Francisco, USA. HLB Panagen

The presentation was titled "The Overlooked Oligo: Why Should We Re-Focus on PNA in Drug Pipelines?" HLB Panagen explained the distinguishing characteristics of PNA, such as its higher binding affinity and stability compared to conventional oligonucleotides, and presented examples of its applications across various research and new drug development fields, as well as the prospects for future expansion.

During the Q&A session following the presentation, participants raised specific questions about the practical applicability of PNA in new drug development. There was also a question regarding whether PNA could unintentionally affect gene expression, especially in comparison to phosphorodiamidate morpholino oligomers (PMOs) commonly used in oligonucleotide therapeutics. HLB Panagen clarified that, due to PNA's strong binding affinity to target sequences, such risks would be relatively low.

This keynote was organized in collaboration with Chemsyns, HLB Panagen’s U.S. distribution partner for PNA. Throughout the event, HLB Panagen and Chemsyns held one-on-one meetings with local pharmaceutical and biotech companies in the U.S., discussing collaboration and commercialization opportunities for PNA-based R&D. Global drug development companies and contract development and manufacturing organizations (CDMOs) expressed significant interest in leveraging PNA for new drug development and potential business partnerships.

Inkeun Jang, CEO of HLB Panagen, stated, "Through this keynote and on-site meetings, it became evident that global drug development companies are highly interested in the technological properties of PNA and its practical potential for new drug development." He added, "We will continue to strengthen our partnership with Chemsyns to expand collaboration and commercialization opportunities for PNA-based R&D in the U.S. and other global markets."

This content was produced with the assistance of AI translation services.